课题基金 / 基金详情

Nighttime Dosing of Anti-Hypertensive Medications: A Pragmatic Clinical Trial

Nighttime Dosing of Anti-Hypertensive Medications: A Pragmatic Clinical Trial
夜间服用抗高血压药物:一项实用的临床试验
批准号:
8465693
负责人:
GARY E ROSENTHAL
金额:
$77.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-30 至 2013-12-31

项目摘要

项目成果

GARY E ROSENTHAL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Two recent small clinical trials reported that hypertensive patients with chronic kidney disease or diabetes who were assigned to take at least one antihypertensive at bedtime had a dramatically lower risk of cardiovascular events. The simplicity of the intervention (changing the timing of medication administration), the prevalence of the underlying condition, and the large potential impact of the intervention on improving health make this area an ideal topic for a pragmatic clinical trial. Thus, the proposed trial will determine the effectiveness of nighttime dosing of antihypertensive medications in patients at risk of adverse cardiovascular events. The study will be conducted at two integrated health systems and will build on the innovative work of the investigative team in: 1) developing electronic medical record (EMR) based patient recruitment strategies; 2) building interactive web-based platforms for obtaining informed consent; 3) extracting research data from EMRs; 4) collecting patient-reported outcomes web-based personal health records; and 5) conducting NIH and VA funded multi-site trials in routine primary care settings to improve management of hypertension. During the UH2 component, the investigators will refine and then implement a number of innovative and highly efficient strategies for patient recruitment, data collection, and obtaining informed consent at the two participating sites. During the UH3 component, the team will conduct randomized pragmatic trial to examine the impact of nighttime antihypertensive dosing. The study will enroll an estimated 1100 patients from the two sites during a seven-month period. Patients will be followed for the subsequent 36-42 months to determine the occurrence of major cardiovascular events. Other study endpoints include clinic and sleep time blood pressure, medication adherence, health related quality of life, symptoms, and healthcare utilization. Eligible patients will be identified using EMR-based algorithms. Informed consent will be obtained using an interactive web-based platform or a 1-800 telephone contact with a study coordinator. Study data will be extracted from EMRs at the two participating sites and from web-based personal health records. PUBLIC HEALTH RELEVANCE: This study will involve conducting a simple and practical clinical trial to determine if taking medication for high blood pressure at night, as opposed to in the morning, lead to a lower risk of cardiovascular disease in patients with hypertension. The study will collect data from electronic medical records and from personal health records and will use an innovative website to collect informed consent from patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
J. NRSA Training Core (TL1)
J. NRSA Training Core (TL1)
J. NRSA Training Core (TL1)
The University of Iowa Clinical and Translational Science Award
  • 批准号:
    8995815
  • 项目类别:
  • 资助金额:
    $352.86万
  • 财政年份:
    2015
  • 负责人:
    GARY E ROSENTHAL
  • 依托单位:
海外基金